Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168227 | 0.86 | FFAR1 (0.49) | GRM5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8623036 | 0.83 | HDAC2 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5966248 | 0.82 | GRM5 (0.50) | GRM5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL28117229 | 0.78 | GRM5 (0.47) | GRM5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6014414 | 0.78 | MAOA (0.50) | GRM5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL28175144 | 0.78 | GRM5 (0.51) | GRM5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29019622 | 0.78 | GRM5 (0.47) | GRM5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29048463 | 0.78 | GRM5 (0.51) | GRM5ADRA1ASLC6A3SIGMAR1MAOA | |
| SCHEMBL2093416 | 0.78 | GRM5 (0.47) | GRM5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16673314 | 0.78 | HDAC1 (0.52) | GRM5HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810967-B1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INT INC (TW) | 2014-07-30 | — | — | EP | disclosed |
| US-8030514-B2 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. (TW) | 2011-10-04 | — | — | US | disclosed |
| US-20090299088-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF PROSTAGLANDINS | CHIROGLATE INTERNATIONAL INC. | 2009-12-03 | — | — | US | disclosed |
| US-7626024-B2 | Processes and intermediates for the preparations of prostaglandins | Irogate International Inc. (CN) | 2009-12-01 | — | — | US | disclosed |
| US-7582779-B2 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. (TW) | 2009-09-01 | — | — | US | disclosed |
| US-7511168-B2 | Processes and intermediates for the preparations of prostaglandins | Wei, Shih-Yi (TW) | 2009-03-31 | — | — | US | disclosed |
| US-20080039637-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039627-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2008-02-14 | — | — | US | disclosed |
| EP-1810967-A1 | Processes and intermediates for the preparations of prostaglandins | Chirogate International Inc. (TW) | 2007-07-25 | — | — | EP | disclosed |
| US-20070167641-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299088-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF PROSTAGLANDINS | PTGES, PTGER1, PTGIS | GRM5 2107/4885HDAC3 4242/4885HDAC4 4442/4885 |
| US-20070167641-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | GRM5 2107/4885HDAC3 4242/4885HDAC4 4442/4885 |
| US-20080039637-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | GRM5 2107/4885HDAC3 4242/4885HDAC4 4442/4885 |
| US-20080039627-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | GRM5 2107/4885HDAC3 4242/4885HDAC4 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.